Multivalent pneumococcal conjugate vaccine - Pfizer

Drug Profile

Multivalent pneumococcal conjugate vaccine - Pfizer

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Pneumococcal vaccines; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pneumococcal infections

Most Recent Events

  • 01 Aug 2017 Pfizer completes a phase I trial in Pneumococcal infections (Prevention, In adults) in USA (IM) (NCT02955160)
  • 02 Nov 2016 Pfizer plans a first-in-human phase I trial for Pneumococcal infections (In adults, Prevention) in USA (IM) (NCT02955160)
  • 01 Nov 2016 Phase-I clinical trials in Pneumococcal infections (Prevention, In adults) in USA (IM) (NCT02955160)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top